Small-Cap REIT ETF ...
Health Care: Drugs
Cadence Pharmaceuticals Inc. (CADX: NASDAQ)
$7.18 -0.10 | -1.37%
05/17/13 - 04:00 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 7.18 |
| 52 Week High | 7.53 |
| 52 Week Low | 2.56 |
| Avg. Daily Vol. (Mil) | 0.31 |
| Beta (3 year) | 1.23 |
| Share Related Items | |
| Mkt Cap (Mil) | 616.06 |
| Shares Out (Mil) | 85.80 |
| Float (Mil) | 52.20 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 3.50 |
| Current Ratio | 3.90 |
| LT Debt/ Equity | 0.55 |
| Total Debt / Equity | 0.60 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 9.36 |
| Price/Book | 12.80 |
| Price/Cash Flow | -7.70 |
| Per Share Data | |
| Earnings | -0.71 |
| Sales | 0.77 |
| Book Value | 0.56 |
| Cash Flow | -0.93 |
| Business Summary | |
|---|---|
| A biopharmaceutical company, which is focused on in-licensing, developing and commercializing product candidates mainly for use in the hospital setting. | |
| General Information | |
| 12481 High Bluff Drive
Suite 200 San Diego, CA 92130 |
|
| www.cadencepharm.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 204 | |
| CEO: Theodore R. Schroeder | |
| Short Interest | |
| Current Month (Mil) | 3.68 |
| Previous Month (Mil) | 4.07 |
| Short Interest Ratio (Days) | 10.60 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -86.10 |
| Return on Investments | -110.00 |
| Profitability | |
| Gross Margin | 60.70 |
| EBIT Margin | -83.90 |
| Profit Margin | 0.00 |
Portfolios with CADX
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Setting Up...
- ContributorBreakout Stocks Of The Week...
- User8 Stocks Under $10 Making B...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- Contributor8 Stocks Below $10 To Avoid
Latest CADX Headlines from TheStreet
- 4 Health Care Stocks Under $10 to Watch 04.16.13 | 03:04 pm
- 5 Stocks Poised for Breakouts 04.05.13 | 02:04 pm
- 5 Stocks Under $10 Triggering Breakouts 03.21.13 | 01:03 pm
- Stocks Under $5: Discount Drug Name
11.29.12 | 06:11 am - 8 Stocks Under $10 Making Big Moves 08.23.12 | 02:08 pm
- Cadence Pharmaceuticals' Management Presents At The 2012 Wedbush PACGROW Life Sciences Management Access Conference (Transcript) 08.14.12 | 09:08 pm
- Cadence Pharmaceuticals' CEO Discusses Q2 2012 Results - Earnings Call Transcript 08.03.12 | 01:08 am
- 7 Stocks Under $10 With Relative Strength 07.06.12 | 02:07 pm
- 8 Stocks Under $10 to Avoid at All Costs 12.23.11 | 12:12 pm
- Pacira: Exparel Approval Easy, Selling Painkiller Harder Challenge 10.31.11 | 11:10 am
Press Releases for CADX
- Cadence Pharmaceuticals Announces Proposed Public Offering Of Common Stock - PR Newswire 11.08.10 | 06:11 am
Partner Headlines for CADX
- Cadence: Not Altering Sales Projections Or Rating In Aftermath Of Product Recall - Seeking Alpha 02.08.12 | 09:02 am
- Cadence Pharmaceuticals: Good For Patients, Bad For Investors - Seeking Alpha 12.26.11 | 08:12 am
- Wedbush Lowers Cadence PT to $10 from $15 - Benzinga 11.23.11 | 01:11 pm
- Company News for November 18, 2011 - Corporate Summary - Zacks 11.18.11 | 10:11 am
- Options Brief: Cadence Pharmaceuticals - Benzinga 07.15.11 | 01:07 pm
- Cadence: Not Unduly Concerned About ANDA Filing Against Ofirmev - Seeking Alpha 07.05.11 | 09:07 am
- 6 Speculative Biotech Stocks Smart Money Loves - Seeking Alpha 05.23.11 | 09:05 am
- Top 15 Most Undervalued Biotech Stocks By Analyst Target Price - Seeking Alpha 04.08.11 | 03:04 pm
- Future Biotech Superstars - Seeking Alpha 03.30.11 | 09:03 am
- Cadence Pharmaceuticals: A Rising Star - Seeking Alpha 03.13.11 | 09:03 am
